Blood test to predict response to immunotherapy
Part of Cancer clinical trials.
This study is testing a blood test (Episwitch CiRT®) that looks at your DNA to see if it can predict whether you will respond to a type of immunotherapy called PD-(L)-1 checkpoint inhibitors. The goal is to see if this test is accurate across many different types of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have stage III or IV cancer
- Your doctor has decided to order the Episwitch CiRT® test as part of your usual care
- You are well enough to be up and about (ECOG score 0, 1, or 2)
- You are a candidate for immunotherapy (PD-1 or PD-L1 checkpoint inhibitors)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is monitoring changes in a cancer protein called PD-L1 in head and neck cancer patients before and during immunotherapy treatment. It aims to better understand how well immunotherapy will work by using regular blood tests.
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
This study looks at blood samples from people with cancer who are starting immunotherapy. Researchers want to find markers that might predict how well the treatment works and whether it could cause side effects.
This study looks at using a blood test that detects tiny pieces of cancer DNA (called ctDNA) to help decide how long patients with advanced melanoma should stay on immunotherapy. It may help some patients safely stop treatment earlier if the blood test shows the cancer is under control.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This trial is testing a simple blood test (using white blood cells) to see if it can predict how well immunotherapy will work for people with advanced cancer. If you are starting immunotherapy soon as your first treatment, this study might help guide your care.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.